Abstract: Disclosed is a method for etching graphene using a DNA sample of a predetermined DNA shape. The DNA sample is preferably placed onto a reaction area of a piece of highly oriented pyrolytic graphite (HOPG), and both the DNA sample and HOPG are then preferably placed into a humidity-controlled chamber. Humidity is preferably applied to the HOPG to produce a film of water across the surface of the DNA sample. Electrical voltage is also applied to the HOPG to create potential energy for the etching process. After the etching is completed, the reaction area is typically rinsed with deionized water.

Abstract: A health care system for a caregiver to monitor and manage sleep metric, patterns and quality for an infant, including: a) a base station in communication with a network, b) one or more sensors in communication with the base station, c) a caregiver communication device in communication with the network; and d) a remote server and associated data store in communication with the network. The remote server is operative to: 1) access information from the information store indicating caregiver typing traits, 2) receive information from the sensors indicating a sleep quality for the infant, 3) receive information from the caregiver communication device indicating a caregiver perception of sleep quality for the infant, 4) recommend at least one caregiver action as a function of the caregiver typing traits, the sleep quality measures and the caregiver perception of the sleep quality; and 5) transmit the recommended action to the caregiver communication device.

Abstract: Disclosed is a method for etching graphene using a DNA sample of a predetermined DNA shape. The DNA sample is preferably placed onto a reaction area of a piece of highly oriented pyrolytic graphite (HOPG), and both the DNA sample and HOPG are then preferably placed into a humidity-controlled chamber. Humidity is preferably applied to the HOPG to produce a film of water across the surface of the DNA sample. Electrical voltage is also applied to the HOPG to create potential energy for the etching process. After the etching is completed, the reaction area is typically rinsed with deionized water.

Abstract: Disclosed is a method for etching graphene using a DNA sample of a predetermined DNA shape. The DNA sample is preferably placed onto a reaction area of a piece of highly oriented pyrolytic graphite (HOPG), and both the DNA sample and HOPG are then preferably placed into a humidity-controlled chamber. Humidity is preferably applied to the HOPG to produce a film of water across the surface of the DNA sample. Electrical voltage is also applied to the HOPG to create potential energy for the etching process. After the etching is completed, the reaction area is typically rinsed with deionized water.

Abstract: A system, method and computer program for enabling signings/dedications on a remote basis is provided. A first computer at a first location is associated with an individual from whom a signature or dedication is required. A second computer at a location where the signing or dedication is required is linked to the first computer so as to provide a two-way audiovisual communication system. The second computer is operate e to receive input from one or more individuals regarding their request for a signature and/or dedication, and to communicate the request to the first computer. The first computer is operable to permit the individual associated with the first computer to review the request, and based on such request provide a signature and/or personalized dedication as an input to an input device connected to the first computer. The first computer transmits the signature and/or personalized dedication from the first computer to the second computer.

Abstract: The Gator Shield is a new product that encapsulates alligator clips and provides finger safe quick connection to distribute power. The Gator Shield secures alligator clips in an electrically insulated housing. The alligator clips are recessed into the housing at a distance to provide a finger safe product. It includes a visual power alert attached to the housing to indicate power to alligator clips. Alligator clip actuation is done through an electrically insulated button. Button color may vary depending on local electrical code and/or customer preference. Housing may or may not be marked with various markings indicating an alpha numeric code (See FIGS. 2, 3 and 5).

Abstract: The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.

Abstract: The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.

Abstract: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) variants, pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such variants.

Abstract: The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.

Abstract: The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.

Abstract: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) variants, pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such variants.

Abstract: A system, method and computer program for enabling signings/dedications on a remote basis is provided. A first computer at a first location is associated with an individual from whom a signature or dedication is required. A second computer at a location where the signing or dedication is required is linked to the first computer so as to provide a two-way audiovisual communication system. The second computer is operate e to receive input from one or more individuals regarding their request for a signature and/or dedication, and to communicate the request to the first computer. The first computer is operable to permit the individual associated with the first computer to review the request, and based on such request provide a signature and/or personalized dedication as an input to an input device connected to the first computer. The first computer transmits the signature and/or personalized dedication from the first computer to the second computer.

Abstract: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) proteins, pharmaceutical compositions comprising FGF21 proteins, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such proteins.

Abstract: Disclosed is a method for etching graphene using a DNA sample of a predetermined DNA shape. The DNA sample is preferably placed onto a reaction area of a piece of highly oriented pyrolytic graphite (HOPG), and both the DNA sample and HOPG are then preferably placed into a humidity-controlled chamber. Humidity is preferably applied to the HOPG to produce a film of water across the surface of the DNA sample. Electrical voltage is also applied to the HOPG to create potential energy for the etching process. After the etching is completed, the reaction area is typically rinsed with deionized water.

Abstract: This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, or metabolic syndrome, or any combination thereof, using such variants.

Abstract: A system, method and computer program for enabling signings/dedications on a remote basis is provided. A first computer at a first location is associated with an individual from whom a signature or dedication is required. A second computer at a location where the signing or dedication is required is linked to the first computer so as to provide a two-way audiovisual communication system. The second computer is operate e to receive input from one or more individuals regarding their request for a signature and/or dedication, and to communicate the request to the first computer. The first computer is operable to permit the individual associated with the first computer to review the request, and based on such request provide a signature and/or personalized dedication as an input to an input device connected to the first computer. The first computer transmits the signature and/or personalized dedication from the first computer to the second computer.

Abstract: The present invention provides a method for etching graphene using a DNA sample of a predetermined DNA shape. The DNA sample is preferably placed onto a reaction area of a piece of highly oriented pyrolytic graphite (HOPG), and both the DNA sample and HOPG are then preferably placed into a humidity-controlled chamber. Humidity is preferably applied to the HOPG to produce a film of water across the surface of the DNA sample. Electrical voltage is also applied to the HOPG to create potential energy for the etching process. After the etching is completed, the reaction area is typically rinsed with deionized water.

Abstract: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) proteins, pharmaceutical compositions comprising FGF21 proteins, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such proteins.

Abstract: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) proteins, pharmaceutical compositions comprising FGF21 proteins, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such proteins.